Results 41 to 50 of about 3,840 (115)

Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data. [PDF]

BMC Pharmacol Toxicol
Mu L, Xu J, Ye X, Jiang Y, Yi Z.
europepmc   +1 more source

Giant prolactinoma with progressive cranial settling and central herniation: a case report. [PDF]

J Med Case Rep
Shahbazi T, Abdollahi Yeganeh S, Borzouei S, Arjipour M.   +3 more
europepmc   +1 more source

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs). [PDF]

Pituitary
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Schilbach K, Lely AJV, Wass JAH, Melmed S, Casanueva FF.   +18 more
europepmc   +1 more source

Cabergoline in the Treatment of Peripartum Cardiomyopathy [PDF]

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, 2016
openaire   +5 more sources

Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes? [PDF]

Rev Assoc Med Bras (1992)
Santos AC, Yela DA, Nakamura RM, Ribas BC, Silva PHRE, Mota B, Benetti-Pinto CL.   +6 more
europepmc   +1 more source

Predictors of biochemical and structural response to medical therapy in patients with active acromegaly following surgery: a real-world perspective. [PDF]

BMC Endocr Disord
Rafieemanesh M, Kachuee MA, Mehrjardi AZ, Khajavi A, Ghorbani M, Mohajeri-Tehrani MR, Hashemi-Madani N, Khamseh ME.   +7 more
europepmc   +1 more source

Efficacy of Local N-Acetylcysteine Administration in Mitigating OHSS Parameters: A Comparative Analysis With Dopaminergic Agonist in the OHSS Model. [PDF]

Int J Endocrinol
Letras-Luna DE, Rosas-Murrieta NH, Pazos-Salazar NG, Flores-Hernández J, Castelán F, Venegas B, Díaz A, Treviño S, Juárez-Serrano D, García-Suastegui WA, Handal-Silva A, Morán-Perales JL.   +11 more
europepmc   +1 more source

Biological mechanisms of dopamine D₂-like receptor agonist therapy in diabetes. [PDF]

Front Endocrinol (Lausanne)
Freyberg Z, Codario RA.
europepmc   +1 more source

Antioxidant and neuroprotective effects of cabergoline

Japanese Journal of Pharmacology, 2000
Norio Oaawa, Naoko Fujita, Ikuko Miyazaki, Ken-ichi Tanaka, Masato Asanuma   +4 more
openaire   +2 more sources

Letter to the Editor Regarding "The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series". [PDF]

J Neurol Surg Rep
Acitores Cancela A, Rodríguez Berrocal V, Pian-Arias H, Díez JJ, Iglesias P.   +4 more
europepmc   +1 more source